Hi there!
We track 70,000+ AI startups and surface hidden job opportunities that never appear on LinkedIn. Tell us what you're looking for, our AI agent does the searching. It's free and you sign up using Google. Go explore!
bioSyntagma
bioSyntagma gives clinicians and researchers a patient-specific view of cancer to inform therapy selection and limit acquired drug resistance. The company’s mPrint molecular fingerprint platform…
bioSyntagma
bioSyntagma gives clinicians and researchers a patient-specific view of cancer to inform therapy selection and limit acquired drug resistance. The company’s mPrint molecular fingerprint platform…
TL;DR
Core offering: mPrint platform: multi-omic, spatially resolved molecular profiling with AI-driven therapy matching
Industry: Biotechnology — precision oncology
Headquarters: St. Louis, Missouri, United States
Founded: 2015
Public funding record (partial): Grants from National Institutes of Health and National Science Foundation reported
Company Overview
Problem Domain
Precision oncology — guiding clinical therapy selection and supporting therapeutic development by revealing spatially resolved tumor biology and actionable biomarkers.
Founded
2015
Industry
Biotechnology
Funding Track Record
1382086
Amount and date reported in company snapshot; investors include National Institutes of Health and National Science Foundation (reported separately)
Investor Signal
“Grants from National Institutes of Health and National Science Foundation”
Founders
What we do
Join the Team
Startup jobs. A lot of them.
Your next opportunity is in here somewhere. Sign up to explore 70,000+ startups and their open roles. No spam. No gamification. Just jobs.
70,000+
Startups
83,000+
Open Roles
4,800+
New This Week